Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by subaru1ion Mar 16, 2024 8:48am
84 Views
Post# 35936384

DEA rescheduling to III enables cannabinoids for pharma

DEA rescheduling to III enables cannabinoids for pharma applications BECAUSE THERE ARE 2 HANDS BEING PLAYED BY THE WHITE HOUSE!!!   Pharma and Politics.

1) FDA/Dept of Human Health & Services: provided scientific and clinical data to the DEA.   This has NOTHING to do with recreational use and EVERYTHING to do with pharmaceutical applications....scientific data and clinical data and this is why the NIH/Dept of Human Health and Services is funding the Libby Study at Keck School of Medicine at USC.   Clinical trial materials provided by LABS, import into U.S. approved by DEA/Dept of Justice.

2) Biden and Harris are in a re-election year, Biden pardons for simple possesion and Harris with Fat Joe rapper talking about the social injustices against blacks and hispanics, 'absurd and patently unfair' commented by Harris and TELLING the DEA 'looking forward to their hard work'.

Now for those with a sweet tooth.....The Libby Study at Keck was started about 9 months or so ago..give or take a few months BUT the CEO of LABS indicated publicly MUCH EARLIER the following...'we have over 20 strong clinical trials, many in late stage'.   Those specific clinical trials LABS is involved with their "large traditional global pharmaceutical partner" could have been started in California, Canada, Israel, Germany, South America, Australia.....a global pharma company has locations GLOBALLY and the ability to do clinical trials with cannabinoids as API's in ANY country where legal!!!!

Does everyone see the 2 plays at hand now?  Pharmaceutical and Political.   
<< Previous
Bullboard Posts
Next >>